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Abstract
Background: Pseudomonas aeruginosa has gained an increasing amount of attention in the treatment of patients
with pneumonia. However, the benefit of empirical combination therapy for pneumonia remains unclear. We
evaluated the effects of adequate empirical combination therapy and multidrug-resistance in bacteremic
Pseudomonas pneumonia on the mortality.
Methods: A retrospective cohort study was performed at the 2,700-bed tertiary care university hospital. We
reviewed the medical records of patients with bacteremic pneumonia between January 1997 and February 2011.
Patients who received either inappropriate or appropriate empirical therapy were compared by using marginal
structural model. Furthermore, we investigated the direct impact of combination therapy on clinical outcomes in
patients with monomicrobial bacteremic pneumonia.
Results: Among 100 consecutive patients with bacteremic Pseudomonas pneumonia, 65 patients were classified in
the adequate empirical therapy group, 32 of whom received monotherapy and 33 combination therapy. In the
marginal structural model, only inadequate therapy was significantly associated with 28-day mortality (p = 0.02), and
multidrug-resistance was not a significant risk factor.
To examine further the direct impact of combination therapy, we performed a subgroup analysis of the 65 patients
who received adequate therapy. Multivariate logistic regression analysis identified absence of septic shock at the
time of bacteremia (OR, 0.07; 95% CI, 0.01-0.49; p = 0.008), and adequate combination therapy (OR, 0.05; 95% CI,
0.01-0.34; p = 0.002) as variables independently associated with decreased all-cause 28-day mortality.
Conclusions: Our study suggests that adequate empirical combination therapy can decrease mortality in patients
with bacteremic Pseudomonas pneumonia.
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Background
Pseudomonas aeruginosa has emerged as a significant
nosocomial pathogen with a substantial frequency of
multidrug resistance (MDR) [1]. Moreover pneumonia
caused by P. aeruginosa is known to be associated with
greater mortality than infection of other sites [2-5].
Hence, treatment of P. aeruginosa pneumonia poses a
great challenge to clinicians. Early studies, mainly of
neutropenic patients with bacteremia, showed that mor-
tality was decreased in patients receiving combination
therapy [6]. However, the results of subsequent clinical
studies on the effect of combination therapy on the
treatment of severe P. aeruginosa infection have been
conflicting [7-11]. These previous studies had significant
limitations, including the enrollment of only small num-
bers of patients infected with different kinds of gram-
negative bacilli and the lack of controls. Furthermore,
the validity of diagnoses of P. aeruginosa pneumonia has
itself been questioned because P. aeruginosa often
* Correspondence: sangho@amc.seoul.kr
1Departments of Infectious Diseases, Asan Medical Center, University of Ulsan
College of Medicine, 388-1 Pungnap-dong, Songpa-gu, Seoul, Republic of
Korea
Full list of author information is available at the end of the article
© 2012 Park et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Park et al. BMC Infectious Diseases 2012, 12:308
http://www.biomedcentral.com/1471-2334/12/308
colonizes the respiratory tract in hospital settings, and it
is often difficult for clinicians to distinguish a colonizer
from a true pathogen [2]. Thus, the isolation of P. aeru-
ginosa from blood cultures, as well as respiratory speci-
mens, constitutes strong evidence of true Pseudomonas
pneumonia.
To help identify the best strategy for antibiotic therapy
in Pseudomonas pneumonia, we evaluated the impact of
empirical combination therapy on mortality in 100 con-
secutive patients with bacteremic P. aeruginosa pneumo-




All patients ≥18 years with P. aeruginosa bacteremic
pneumonia between January 1997 and February 2011
were included. Patients with blood cultures positive for
P. aeruginosa were identified from the computerized
database of the clinical microbiology unit. Infectious dis-
eases doctors then reviewed the medical records of these
patients and collected demographic, clinical, and micro-
biological data. Ultimately, only patients with Pseudo-
monas pneumonia (see below) were included in the
analysis. Patients with polymicrobial infections were
excluded. The study was approved by the Asan Medical
Center Institutional Review Board (S2012-1034-0001),
and the requirement for patient consent was waved due
to the retrospective nature of the study.
Definitions
Bacteremia was defined as ≥ 1 positive blood culture for
P. aeruginosa and the presence of the clinical features
compatible with infection. If a patient had undergone re-
current episodes of P. aeruginosa bacteremia during the
study period, only the first episode was considered.
Pneumonia was defined as presence of: (1) new radio-
graphic infiltration; (2) one or more of the following
symptoms consistent with pneumonia (fever, cough,
pleuritic chest pain, and dyspnea); and (3) isolation of P.
aeruginosa from cultures of bronchoalveolar lavage
(BAL) fluid or appropriate respiratory specimens [12,13].
The categories of pneumonia have been previously
defined [14,15]. Empirical antibiotic therapy was consid-
ered adequate if therapy given intravenously within 48 h
of the onset of pneumonia included antimicrobials to
which the isolate was susceptible. Patients who received
adequate treatment were stratified into 2 groups: a
monotherapy group that received only 1 active anti-
microbial, and a combination therapy group that simul-
taneously received 2 active antimicrobials [16].
Antimicrobial susceptibility testing was performed using
the MicroScan system with the Neg Breakpoint Combo
Panel 44 (Siemens Healthcare Diagnostics Inc., West
Sacramento, CA) according to standard criteria of the
Clinical and Laboratory Standards Institute [17]. MDR
was defined as resistance to more than three classes of
antibiotics such as anti-pseudomonal beta-lactams, car-
bapenems, fluoroquinolones, and aminoglycosides [18].
Statistical analysis
All statistical analyses were performed using SAS soft-
ware, version 9.1 (SAS Institute Inc, Cary, NC). Marginal
structural models were used to estimate the difference in
mortality between the adequate therapy group and the
inadequate therapy group. Careful adjustment was made
using weighted Cox proportional-hazards regression
models that were based on the inverse-probability-of-
treatment weighted (IPTW) method in order to reduce
the effect of potential confounding factors and selection
bias in this observational study [19]. IPTW estimation
relies on multivariable logistic regression analysis. All
variables with a p value < 0.2 on univariable analysis
were then introduced into the multivariable logistic re-
gression model, and a backwards stepwise logistic re-
gression was carried out. Sex, age, underlying diseases,
multidrug resistance, McCabe score, APACHE II score,
Pitt bacteremia score, clinical pulmonary infection score
(CPIS), type of pneumonia, and use of previous antibio-
tics were classified as independent variables for the pur-
poses of this study. P value ≤ 0.05 was considered
statistically significant.
Results
During the study period 1,361 patients with P. aerugi-
nosa bacteremia were identified from our hospital
records. One hundred (7.3%) patients with concomitant
pneumonia were eventually included in the analysis. The
demographics, clinical features, microbiologic character-
istics and clinical outcomes of these patients are shown
in Table 1. Hematologic malignancy (34%) was the most
common underlying disease, followed by solid cancer
(23%). Of the 100 cases, 37 (37%) originated in the
community (18 community-acquired and 19 healthcare-
associated infections). Thirty-eight (38.0%) patients pre-
sented with septic shock. Sixty-five patients (65.0%) were
assigned to the adequate empirical therapy group, 32
(49.2%) of whom received monotherapy and 33 (50.8%)
combination therapy. The antimicrobials used in mono-
therapy were as follows: ceftazidime (n = 10), cefepime
(n = 2), carbapenem (n = 8), piperacillin-tazobactam (n =
7), and ciprofloxacin (n = 5). The remainder of the
patients received combination therapy: piperacillin-
tazobactam plus ciprofloxacin (n = 11), cefoperazone-
sulbactam plus aminoglycoside (n = 9), ceftazidime plus
aminoglycoside (n = 8), ceftazidime plus ciprofloxacin
(n = 3), and carbapenem plus ciprofloxacin (n = 2).
MDR pathogens were commonly found in the inadequate
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Age (median years, range) 59 (53–67) 60 56 61 0.24
Male gender 74 (74.0) 27 (84.4) 24 (72.7) 23 (65.7) 0.22
Underlying disease
Hematologic malignancy 34 (34.0) 12 (37.5) 14 (42.4) 8 (22.9) 0.21
Solid organ malignancy 23 (23.0) 8 (25.0) 12 (36.4) 3 (8.6) 0.02
Neurologic disease 14 (14.0) 7 (21.9) 0 7 (20.0) 0.01
Immunosuppression 22 (22.0) 6 (18.8) 10 (30.3) 6 (17.1) 0.13
Structural lung disease 8 (8.0) 2 (6.3) 4 (12.1) 2 (5.9) 0.65
Congestive heart failure 9 (9.0) 2 (6.3) 1 (3.0) 6 (17.1) 0.13
Hemodialysis 10 (10.0) 2 (6.3) 1 (3.0) 7 (20.0) 0.07
Liver cirrhosis 5 (5.0) 1 (3.1) 2 (6.1) 2 (5.7) 0.99
Biliary disease 2 (2.0) 0 0 2 (5.7) 0.33
McCabe score <0.001
Non-fatal 42 (42.0) 13 (40.6) 7 (21.2) 22 (62.9)
Ultimately fatal 44 (44.0) 18 (56.3) 20 (60.6) 6 (17.1)
Rapidly fatal 14 (14.0) 1 (3.1) 6 (18.2) 7 (20.0)
APACHE II score, median (IQR) 21 (16–26) 18.5 (13–22) 20 (17–24.5) 23 (14–27) 0.08
Pitt bacteremia score, median (IQR) 3 (1–5) 2 (0–4) 3 (2–5) 4 (2–6) 0.05
CPIS, median (IQR) 6 (5–7) 6 (5–7) 6 (5–7) 6 (5–7) 0.57
Type of pneumonia 0.01
Community-acquired 18 (18.0) 3 (9.4) 11 (33.3) 4 (11.4)
Healthcare-associated 19 (19.0) 8 (25.0) 6 (18.2) 5 (14.3)
Hospital- acquired 44 (44.0) 15 (46.9) 15 (45.5) 14 (40.0)
Ventilator-associated 19 (19.0) 6 (18.8) 1 (3.0) 12 (34.3)
Initial manifestation within 24 h 0.22
Bacteremia without SIRS 6 (6.0) 2 (6.3) 2 (6.1) 2 (5.7)
Sepsis 35 (35.0) 17 (53.1) 8 (24.2) 10 (28.6)
Severe sepsis 21 (21.0) 6 (18.8) 7 (21.2) 8 (22.9)
Septic shock 38 (38.0) 7 (21.9) 16 (48.5) 15 (42.9)
MDR-P. aeruginosa 23 (23.0) 6 (18.8) 2 (6.1) 15 (42.9) 0.001
Previous antibiotic therapy 55 (55.0) 17 (30.9) 11 (20.0) 27 (49.1) 0.009
Initial antimicrobial administration within 24 h 94 (94.0) 29 (90.6) 32 (96.9) 33 (94.3) 0.60
Total duration of therapy, median days (IQR) 14 (8–21) 15 (9–19) 14 (8–22) 14 (7–21) 0.71
Total length of hospital stay, median days (IQR) 37.5 (19–75) 39 (19–94) 28 (13–60) 52 (26–82) 0.10
Length of hospital stay before bacteremia,
median days (IQR)
12.5 (0–39) 9 (0–29.5) 0 (0–19.5) 29 (9–59) 0.005
Length of hospital stay after bacteremia,
median days (IQR)
16.5 (7–36.5) 18.5 (10.8-52.5) 16 (6.5-34) 17 (7–33) 0.21
Overall mortality
7-day mortality 21 (21.0) 5 (15.6) 6 (18.2) 10 (28.6) 0.382
14-day mortality 30 (30.0) 8 (25.0) 6 (18.2) 16 (45.7) 0.035
28-day mortality 51 (51.0) 17 (53.1) 10 (30.3) 24 (68.6) 0.01
Data are presented as number (%) unless otherwise specified.
IQR = interquartile range, CPIS = Clinical Pulmonary Infection Score, MDR = multidrug-resistant.
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therapy group (42.9% [15 of 35] vs. 12.3% [8 of 65], p <
0.001). Among the 65 patients in the adequate therapy
group, there was no significant difference in terms of
the emergence of antimicrobial resistance between
the monotherapy and combination therapy group (21.9%
[7/32] and 12.1% [4/33], respectively) (p = 0.29). How-
ever, the 2-week bacteria eradication rate (54.5% [18/33]
vs.18.8% [6/32], p = 0.04) and the 4-week eradication rate
(54.5% [18/33] vs. 28.1% [9/32], p = 0.04) were signifi-
cantly higher in the combination therapy group than the
monotherapy group. There were no subsequent episodes
of Pseudomonas pneumonia after 1 month, but there
were 6 subsequent episodes within the first 6 months (2
patients in the inadequate therapy group [5.7%], 1 patient
in adequate monotherapy group [3.1%], and 3 patients in
adequate combination therapy group [9.1%]). However,
there were no deaths due to recurrent P. aeruginosa in-
fection, and all patients with subsequent episodes
demonstrated full recoveries.
We identified 14 patients who had coinfection at the
time of Pseudomonas pneumonia (6 patients in the inad-
equate therapy group and 8 patients in the adequate
therapy group), though the rates of coinfection were not
significantly different between the monotherapy group
(9.4% [3 of 32]) and the combination therapy group
(15.2% [5 of 33], p = 0.71). Of these 14 patients, 8
patients died (4 patients in inadequate therapy, 2
patients in monotherapy, and 2 patients in the combin-
ation therapy group), but there were no deaths due to
coinfection in either group.
The overall all-cause 28-day mortality was 51.0% (51
of 100). The 28-day mortality was significantly higher in
the inadequate therapy group than the adequate therapy
group (68.6% [24/35] vs. 41.5% [27/65], p = 0.01). Vari-
ables such as sex, age, MDR, McCabe score, APACHE II
score, Pitt bacteremia score, CPIS, and the use of previ-
ous antibiotics (which were determined to be significant
by univariate analysis) were subjected to logistic regres-
sion modeling in order to identify the independent risk
factors for all-cause mortality. Multivariate analysis indi-
cated that the APACHE II score (adjusted odds ratio
[AOR]: 1.08; 95% confidence interval [CI]: 1.02–1.15;
p = 0.01) and inadequate therapy (AOR: 2.73; 95% CI:
1.11–6.71; p = 0.03) were independently associated with
all-cause 28-day mortality (Additional file 1: Table S1).
The marginal structural model was estimated using
multiple logistic regression analysis. To reduce the
effects of potential confounding factors and selection
bias, additional analyses were performed with covari-
able adjustment using IPTW. These additional analyses
showed that only inadequate therapy was significantly
associated with 28-day mortality (AOR: 3.02; 95% CI:
1.15–7.93; p = 0.02) and that MDR was not a signifi-
cant risk factor (data not shown).
To further examine the direct impact of combination
therapy, we performed a subgroup analysis of the 65
patients who received adequate therapy. In univariate
analysis, variables that were significantly associated with
28-day mortality included underlying hematologic malig-
nancy, Pitt bacteremia score, initial clinical manifestation
of bacteremia, and monotherapy. Multivariate logistic
regression analysis identified the absence of septic shock
at the time of bacteremia (AOR, 0.07; 95% CI, 0.01-0.49;
p = 0.008), and combination therapy (AOR, 0.05; 95% CI,
0.01-0.34; p = 0.002) as variables that were independently
associated with decreased all-cause 28-day mortality
(Table 2).
Discussion
In our present study, we evaluated the impact of empir-
ical combination therapy on clinical outcomes in 100
consecutive patients with monomicrobial bacteremic
Pseudomonas pneumonia. Adequate empirical combin-
ation therapy was associated with significantly lower 28-
day mortality.
Despite the high mortality rates in patients with P.
aeruginosa pneumonia, it is still not clear how best to
treat Pseudomonas pneumonia. Paul et al., in their meta-
analysis of 64 randomized trials, compared the clinical
outcomes of beta lactam monotherapy and beta lactam-
aminoglycoside combination therapy for the treatment
of sepsis in immunocompetent patients [7]. In their
study, beta lactam–aminoglycoside combination therapy
was not associated with decreased mortality. On the
other hand, Safdar and colleagues previously examined
the impact of combination therapy on patients with
gram-negative bacteremia and found a survival benefit
associated with combination therapy in the subgroup of
patients with P. aeruginosa bacteremia, demonstrating
an approximately 50% reduction in mortality (OR: 0.50;
95% CI: 0.32-0.79) [8]. These differing results may have
been due to the limitations of the earlier studies, includ-
ing: (1) the combinations of different pathogens
reported; (2) the greatly varying proportion of patients
with pneumonia (range: 14%-100%); (3) the use of ami-
noglycoside as a monotherapy, which is not currently
considered an appropriate therapy for P. aeruginosa in-
fection; and (4) the possibility of P. aeruginosa
colonization of the respiratory tract was not excluded.
To overcome these limitations, we included a large
number of consecutive patients with monomicrobial
bacteremic Pseudomonas pneumonia in our study.
In our present analyses, adequate empirical therapy
was associated with a significant reduction in mortality
after 7 days. Analysis of the adequate empirical therapy
group revealed that combination therapy was a variable
independently associated with decreased 28-day mortal-
ity. One possible explanation for the decreased mortality
Park et al. BMC Infectious Diseases 2012, 12:308 Page 4 of 6
http://www.biomedcentral.com/1471-2334/12/308
could be a reduced frequency of emergence of anti-
microbial resistance. However, there was no significant
difference between the emergence of antimicrobial re-
sistance in the monotherapy group (21.9% [7/32]) and
the combination therapy group (12.1% [4/33], p = 0.29).
Even in cases in where antimicrobial resistance emerged,
only 3 patients (3 of 7) and 1 patient (1 of 4) died, re-
spectively. Thus, the emergence of resistance may not
affect the mortality rate. In contrast, the 2-week (18.8%
vs. 54.5%, p = 0.04) and 4-week bacteria eradication rates
(28.1% vs. 54.5%, p = 0.04) after bacteremia were signifi-
cantly higher in the combination therapy group than in
the monotherapy group. Because there was no signifi-
cant difference in terms of the emergence of antimi-
crobial resistance between the monotherapy and
combination therapy groups, these findings suggest that
empirical combination therapy may contribute to the re-
duction in mortality by accelerating eradication. Hence,
the manner in which combination therapy decreases
mortality in patients with P. aeruginosa infection is an
interesting question. Unfortunately, we did not perform
a prospective study that could evaluate this and future
analyses of this type will be required to do so.
The present study has some limitations. First, it was
retrospective and performed at a single center, so there
is the potential for bias that would limit the ability to
draw a firm conclusion about the direct impact of anti-
microbial therapy. However, it has been shown that elab-
orate statistical methods, such as the marginal structural
model using IPTW, provide a better method of control
for confounding influences by improving the adjustment
of differences between treatment groups [20]. Further-
more, we tried to evaluate the possible factors that could
affect the clinical outcomes of patients with pneumonia
as much as possible. Second, our study included only
patients with bacteremia, so our finding may not be dir-
ectly applicable to Pseudomonas pneumonia without
bacteremia.
Conclusions
In conclusion, our data strongly suggest that adequate
empirical combination therapy can decrease mortality in
patients with bacteremic Pseudomonas pneumonia. Add-
itional prospective studies are therefore warranted.
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Table 2 Logistic regression analysis of the risk factors for







OR (95% CI) OR (95% CI)
Age 1.00 (0.96-1.04) .98
Male gender 0.48 (0.14-1.76) .27
Underlying disease




Structural lung disease 0.25 (0.03-2.31) .22
Neurologic disease 0.21 (0.02-1.81) .15
Congestive heart failure 2.96 (0.26-34.42) .39
Hemodialysis 0.69 (0.06-8.05) .77
Immunosuppression 0.62 (0.20-1.93) .41
McCabe score
Non-fatal 0.57 (0.09-3.38) .54
Ultimately fatal 1.20 (0.24-6.11) .83
Rapidly fatal 1.0 (referent)
APACHE II score 1.04 (0.97-1.11) .32
Pitt bacteremia score 1.21 (0.96-1.51) .10
CPIS 1.06 (0.73-1.54) .77
Type of pneumonia
Community-acquired 1.00 (0.16-6.26) .99
Healthcare-associated 0.74 (1.12-4.73) .75
Hospital- acquired 1.02 (0.19-5.37) .98
Ventilator-associated 1.0 (referent)
MDR-P. aeruginosa 0.43 (0.08-2.30) .32
Previous antibiotic therapy 1.42 (0.53-3.86) .49
Initial manifestation within 24 h
Sepsis 0.36 (0.11-1.17) .09 0.07 (0.01-0.49) 0.008
Severe sepsis 0.29 (0.07-1.21) .09 0.13 (0.02-0.89) 0.04
Septic shock 1.0 (referent)
Type of adequate empirical therapy
Monotherapy 0.38 (0.14-1.06) .06 0.05 (0.01-0.34) 0.002
Combination therapy 1.0 (referent)
MDR = multidrug-resistant.
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